For pediatric-onset treatment-resistant epilepsy, cannabinoids are effective as an adjunctive treatment for reducing seizure frequency by 50 percent or more, according to a review published online March 6 in the Journal of Neurology, Neurosurgery & Psychiatry. More effective than placebo for reducing seizure frequency, achieving seizure freedom.
While they are similar in some ways, there are important differences between hemp oil and CBD oil. As a consumer, it’s easy to get confused by phrases such as “cannabis oil” and “marijuana oil,” especially when many companies seem to use these terms interchangeably. Let’s take a closer look at hemp oil and CBD oil to learn how to distinguish the two. Hemp and marijuana are cousins in the plant world. Hemp oil and CBD oil come from different strains of the Cannabis sativa plant. However, hemp oil contains low levels of CBD – typically less than 25 parts per million – while CBD oil can be up to 15% CBD. Because the plants are related, some unscrupulous sellers of hemp oil are trying to market it for its medicinal value, which is negligible.
Cannabidiol is an effective and generally well-tolerated add-on treatment for drop seizures in patients with Lennox-Gastaut syndrome, according to research published in The Lancet. “Patients with Lennox-Gastaut syndrome, a rare, severe form of epileptic encephalopathy, are frequently treatment resistant to available medications,” Elizabeth A. Thiele, MD, from the pediatric epilepsy program at Massachusetts General Hospital, and colleagues wrote. “No controlled studies have investigated the use of cannabidiol for patients with seizures associated with Lennox-Gastaut syndrome.”
New data in The Lancet provides further support for GW Pharma’s drug, Epidiolex, for the treatment of a rare form of epilepsy. GW Pharmaceuticals has achieved encouraging Phase III results for Epidiolex, which have been published in leading scientific journal, The Lancet. The company’s lead candidate is being developed for the treatment of epilepsy – a condition characterized by the abnormal firing of neurons in the brain, leading to seizures. In particular, the company targets Lennox-Gastaut syndrome, a rare, lifelong form of epilepsy, which causes significant developmental delays.
Marijuana’s effect on the body has garnered more and more interest as it becomes legal for medical and recreational use in different states. People who are against marijuana legalization cite the potential for addiction and other dangerous side effects, but a new report may debunk this popularly-held belief. On Dec. 13, the World Health Organization (WHO) announced that a cannabis compound called cannabidiol (CBD) “could have therapeutic value” for epilepsy-related seizures. Additionally, the WHO says that CBD is not likely to be misused or create dependence, unlike other cannabis compounds like Tetra Hydro Cannabinol (THC).
Since medicinal cannabis has become a more commonplace alternative for a well-established list of ailments, patients are finding a place for it next to their Advil and Tums. But unlike many other chronic illnesses that can be managed with over-the-counter supplements, epilepsy requires a specific cocktail of chemicals not readily available at the local corner store.
WASHINGTON DC — Patients with intractable epilepsy in Alabama felt better overall one year after initiating a daily cannabidiol (CBD) regimen, according to a study presented here, despite also reporting declining social support and more stressful events over the course of the year. Epilepsy patients started taking daily doses of CBD. One year later, a significant number felt better. The state-funded study did not directly assess CBD’s impact. “I can’t say that” CBD was a factor, said lead researcher Barbara Hansen, now a sociology professor at Henderson State University (Arkansas). She did confirm that every patient in the study was indeed administered CBD, when she spoke to Leafly.com at the American Epilepsy Society annual meeting earlier in December.
It’s a buzzy trend in the wellness world, and while CBD is one of the compounds found in the cannabis plant, don’t worry — it won’t get you high. Here’s what you need to know about the latest ingredient everyone’s talking about. What is CBD? CBD is the abbreviation for cannabidiol, one of the many cannabinoids, or chemical compounds, found in marijuana and hemp. You’re probably already familiar with THC, which is another compound found in the cannabis plant. But unlike THC, CBD is not psychoactive. In other words, it’s not what gets you stoned. It’s also different from medical marijuana, which has been shown to reduce pain.
Cell-sized cannabis factories could soon be producing medical treatments for epilepsy. A non-psychoactive compound found in marijuana plants called cannabidivarin (CBDV) has shown promise in the treatment of severe cases of epilepsy. However, to treat just 10 per cent of people with epilepsy would require around 1500 tonnes (tons) of pure CBDV. To obtain this amount using current methods, you would need to plant large quantities of marijuana and extract their small supply of CBDV. “There’s so little of this chemical in plants it would actually be impossible to harvest it by traditional means,” says Kevin Chen, who runs Hyasynth Bio, a start-up in Montreal, Canada.
Treatment with cannabidiol reduces some major symptoms in mice with a genetic condition recapitulating Dravet syndrome, a devastating childhood brain disorder. Cannabidiol is a non-intoxicating substance among the several active compounds derived from Cannabis plants. This molecule can also be produced synthetically. The results of its use to treat Dravet syndrome are reported in the latest edition of the Proceedings of the National Academy of Sciences, PNAS.
Zynerba Pharmaceuticals has reported that its cannabis-based epilepsy gel ZYN002 (cannabidiol [CBD] gel) has failed to meet the primary point in a phase 2 clinical trial. The trial dubbed as STAR 1 was held in 188 adult epilepsy patients with focal seizures across 14 sites in Australia and New Zealand. When compared to placebo, ZYN002 during the treatment period could not show a statistically significant decrease in focal seizures in comparison to the baseline period for either the high or low dose cohorts. STAR expands to Synthetic Transdermal Cannabidiol for the Treatment of Epilepsy. The patients in the phase 2 trial were randomized to be treated during a 12-week period for every 12 hours with either 195mg of ZYN002 4.2% CBD gel, 97.5mg of ZYN002 4.2% CBD gel or placebo gel. The primary...
New research published in Epilepsia, a journal of the International League Against Epilepsy (ILAE), suggests that an investigational neurological treatment derived from cannabis may alter the blood levels of commonly used anti-epileptic drugs. It is important for clinicians to consider such drug interactions during treatment of complex conditions.